Yoshitaka Tanaka
Hoofd Techniek/Wetenschap/O&O bij NISSUI PHARMACEUTICAL CO., LTD.
Oorsprong van het eerstegraads netwerk van Yoshitaka Tanaka
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Medical Specialties | 13 | |
CellGenTech, Inc.
 CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Yoshitaka Tanaka via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Major Banks | Corporate Officer/Principal | |
| NISSUI CORPORATION | Food: Meat/Fish/Dairy | Chief Tech/Sci/R&D Officer | |
| LEADER ELECTRONICS CORPORATION | Electronic Equipment/Instruments | Director/Board Member | |
| Tokyo Institute of Technology | College/University | Graduate Degree | |
| Nihon University | College/University | Undergraduate Degree | |
Anaeropharma Science, Inc.
 Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Biotechnology | Director/Board Member | |
| Toyo University | College/University | Corporate Officer/Principal | |
| Japan Association of Clinical Reagents Industries | Chairman | ||
Nissui Pharma Medical Sales Co., Ltd.
 Nissui Pharma Medical Sales Co., Ltd. Pharmaceuticals: MajorHealth Technology Nissui Pharma Medical Sales Co., Ltd. engages in the manufacture, sale, import and export of medicine and health foods. The company was founded on June 9, 2016 and is headquartered in Tokyo, Japan. | Pharmaceuticals: Major | Director/Board Member Comptroller/Controller/Auditor Director/Board Member | |
| Japanese Committee For Clinical Laboratory Standards | Director/Board Member | ||
| The Federation of Pharmaceutical Manufacturers Assoc of Japan | Director/Board Member | ||
| The Japan Federation of Medical Devices Associations | Director/Board Member | ||
Watervein Partners KK
 Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi. | Investment Managers | Private Equity Investor |
Statistieken
Internationaal
| Japan | 13 |
| Verenigde Staten | 2 |
Sectoraal
| Consumer Services | 4 |
| Finance | 3 |
| Health Technology | 3 |
| Consumer Non-Durables | 2 |
| Electronic Technology | 2 |
Operationeel
| Director/Board Member | 17 |
| Sales & Marketing | 9 |
| Corporate Officer/Principal | 7 |
| Comptroller/Controller/Auditor | 4 |
| Independent Dir/Board Member | 3 |
Sterkste connecties
- Beurs
- Insiders
- Yoshitaka Tanaka
- Bedrijfsconnecties
